Vaccine access amid political turmoil in Venezuela is the backdrop of institute director Richard Marlink’s comments, for a story published by Devex, about COVAX and a global response to the pandemic.
epidemics
The World According to COVID-19
It’s been a year since COVID-19 was declared a global pandemic. Rutgers Global Health Institute core faculty members discuss the health crisis in relation to their own areas of expertise and professional practice.
Rutgers professor discusses COVAX initiative, U.S. involvement
In an interview with The Daily Targum, institute director Richard Marlink explains the international collaboration to distribute COVID-19 vaccines more equitably worldwide.
Rutgers Global Health Institute Launches Program to Help Small Businesses Impacted by the COVID-19 Pandemic
The three-part program provides guidance on safe operations and related support services for small businesses and nonprofits in New Jersey’s low-income and minority communities.
Medical experts: J&J vaccine is just as effective as vaccines by Pfizer, Moderna
Following the FDA’s emergency approval of Johnson & Johnson’s COVID-19 vaccine, ROI-NJ published a collection of health experts’ perspectives that includes institute director Richard Marlink’s comments about vaccine efficacy.
Radio Interview: Marlink Discusses WHO, Vaccines, and COVAX
In an interview for WRSU Rutgers Radio, institute director Richard Marlink offers perspective on the importance of a global response to COVID-19, vaccine infrastructure in Africa, vaccine production and safety, and the World Health Organization.
The Impact of the U.S. Re-engaging with the World Health Organization
The importance of a global COVID-19 vaccination strategy and how WHO involvement benefits the U.S. overall are topics that institute director Richard Marlink discusses in this Q&A.
Race to Vaccinate
Appearing on CNBC’s Power Lunch, core faculty member and Rutgers vice chancellor Reynold Panettieri discusses the Johnson & Johnson COVID-19 vaccine, infection rates and hospitalizations, and effective public health measures.
When it comes to vaccine efficacy, here’s why 94% isn’t much different than 72%
In an interview about the efficacy of COVID-19 vaccines, institute director Richard Marlink responds to public opinion about the differences among vaccines that are authorized or in the pipeline for use in the United States.
Social and Structural Factors, Not Biology, are Strong Influencers of Racial Disparities in COVID-19 Mortality
Racial disparities in COVID-19 mortality in the U.S. are associated with social factors like income, education, and internet access, according to a Rutgers study published in the Journal of Racial and Ethnic Health Disparities.